Q1 EPS Forecast for CytomX Therapeutics Decreased by Analyst

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Investment analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of CytomX Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.65) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.

Several other research firms have also weighed in on CTMX. Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Cantor Fitzgerald raised their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Guggenheim lifted their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $12.00 in a report on Monday. Finally, Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research report on Monday. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.22.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $4.77 on Wednesday. The stock has a market capitalization of $810.96 million, a price-to-earnings ratio of -119.13 and a beta of 2.44. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $8.21. The stock’s 50 day moving average price is $5.28 and its two-hundred day moving average price is $4.10.

Institutional Investors Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new position in CytomX Therapeutics during the 4th quarter valued at about $208,000. Empowered Funds LLC bought a new stake in CytomX Therapeutics during the 4th quarter worth approximately $133,000. XTX Topco Ltd raised its stake in shares of CytomX Therapeutics by 63.9% in the fourth quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 18,705 shares during the last quarter. Virtus Investment Advisers LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $270,000. Finally, Twinbeech Capital LP bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $75,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Insider Buying and Selling at CytomX Therapeutics

In other CytomX Therapeutics news, CFO Christopher Ogden sold 19,323 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $124,053.66. Following the completion of the sale, the chief financial officer owned 296,948 shares in the company, valued at approximately $1,906,406.16. The trade was a 6.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Sean A. Mccarthy sold 118,969 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the transaction, the chief executive officer owned 1,078,922 shares in the company, valued at approximately $6,926,679.24. The trade was a 9.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is owned by company insiders.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
• Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
• Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
• Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
• Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
• Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
• Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
• Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
• Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.